Of note, high blood EGFR mutation positivity in the First-SIGNAL study was also associated with more aggressive baseline tumour characteristics (e.g., greater number of metastatic sites); Mok et al (2015) also hypothesised that the changes in outcomes with erlotinib may have been linked to increases in tumour burden or metastases. This evidence concerns the gene EGFR and neoplasm.